About
Convexia builds autonomous AI agents that scout, scientifically evaluate, and operationally advance overlooked drug assets. It targets small and mid-sized pharmaceutical companies, biotech investors, computational biotechs, and drug-development operators, differentiating through an AI-native workflow it says operates 10x faster and 20x leaner than incumbents.
Market
Convexia competes in AI-enabled biopharma asset discovery, drug-development diligence, clinical-operations planning, and pharmaceutical partnering. It positions itself as an AI-maximalist pharma platform rather than only a point solution, combining autonomous agents across sourcing, scientific evaluation, market and IP analysis, clinical operations, and business development. Its stated differentiation is an end-to-end, asset-centric workflow designed to operate 10x faster and 20x leaner than traditional processes, while competitors tend to focus more narrowly on deal intelligence, commercial forecasts, biomedical knowledge, or computational drug discovery.
Convexia targets small and midsize pharmaceutical companies, biotech venture capital firms, computational biotechs, and experienced drug-development operators. Its likely buyers are teams responsible for asset sourcing, scientific diligence, clinical planning, market analysis, or partnering who want to accelerate drug search and evaluation.
At a Glance
Problem
Convexia targets the drug-sourcing and diligence bottleneck in pharmaceutical development. The company describes pharma as a bloated, trillion-dollar industry in which potentially valuable or life-saving drugs are overlooked, abandoned, or shelved because diligence is still performed manually. The economics are severe: drug development can take more than 10–15 years, roughly 90% of clinical development fails, and an older Tufts estimate put the cost per approved drug at $802 million in 2000 dollars. The killer use case is therefore finding overlooked preclinical, abandoned, or shelved assets and rapidly deciding whether they are worth acquiring, developing, or passing on before competitors do.
Product / Service
Convexia is building an end-to-end AI-native drug-asset sourcing and evaluation platform. Its specialized agents scan structured and unstructured global data for candidates, run computational assessments of binding, toxicity, ADME/PK, immunogenicity, and mechanism, analyze market and IP dynamics, simulate clinical and operational risks, and produce probability-of-success assessments. The system combines more than 50 models with specialist PhD and KOL review. Convexia claims this approach can operate 10 times faster and 20 times leaner than incumbent processes, replacing months of manual diligence with a faster go/no-go workflow.
The near-term delivery model is modular: customers can license individual components, purchase diligence reports or subscriptions, and participate in pilots. Convexia says it is initially working with pharma, biotech, and investment groups, while its longer-term ambition is to acquire assets, run trials through CRO partners rather than an internal wet lab, and sell successful programs to strategic buyers. In this model, the product is both enterprise software for sourcing and diligence and, eventually, an AI-operated pharma business.
Market
Convexia sits at the intersection of AI-powered drug discovery, drug repurposing, life-sciences software, and pharmaceutical business development. Its closest public comparables are adjacent rather than exact copies: Insilico Medicine operates a generative-AI drug-discovery pipeline, Recursion and Exscientia are established AI drug-discovery companies, and BenevolentAI has demonstrated computational drug-repurposing work. Convexia’s stated differentiation is its focus on finding and evaluating existing, overlooked assets and connecting scientific diligence with market, clinical, operational, and eventual business-development decisions, rather than primarily designing new molecules.
The company was founded in 2025 and is listed by Y Combinator as an active Summer 2025 company in AI-powered drug discovery biotech and drug delivery. PitchBook reports $500,000 raised, while Convexia’s own materials describe an early commercial phase of licensing platform components and running pilots with pharma, biotech, and investment groups. Public evidence does not identify named customers, disclosed clinical assets, or verified recurring revenue, so the best-supported characterization is pilot-stage and early commercialization rather than scaled revenue; the company has published paid entry points and is seeking pilot customers, but those offers alone do not establish realized revenue.
Founders & Leadership
Funding History
Y Combinator
Recent News
A company profile describes Convexia as an AI platform automating pharmaceutical drug discovery and development, with a focus on drug-asset evaluation. It identifies founders Ayaan Parikh and Rahul Vijayan as Stanford computer science dropouts who previously co-founded and exited three startups.
The analysis presents Convexia as an AI-maximalist pharma company focused on uncovering overlooked drug assets and reports a funding round size of $500,000. Its title references $1 million, so the reported amount is internally inconsistent.
PitchBook’s company profile records that Convexia had raised $500,000 and identifies five of eight investors. The profile describes the company as developing AI-native pharmaceutical asset platforms based on agent-driven analysis.
Active Roles
1Business Model
Convexia’s near-term commercial model centers on pilots for customers seeking faster drug sourcing and evaluation; public pricing details were not disclosed. Longer term, it plans to acquire drug assets, run clinical trials, and sell them for profit.